SIMPLIFIED MEAL BOLUS STRATEGIES FOR THE OMNIPOD® 5 AUTOMATED INSULIN DELIVERY (AID) SYSTEM IN PEOPLE WITH TYPE 2 DIABETES (T2D): SUB-ANALYSIS OF THE SECURE-T2D STUDY
Recommended Citation
Davis G, Pasquel F, Huffman D, Peters A, Parker J, Laffel L, Romeo G, Mathew J, Castorino K, Kruger D, Dungan K, Kipnes M, Jauch E, Oser T, Shah V, Horowitz B, Carlson A, Warren M, Deeb W, Buse J, Reed J, Berner J, Blevins T, Bajaj C, Kanapka L, Raghinaru D, Ly T, Beck R. SIMPLIFIED MEAL BOLUS STRATEGIES FOR THE OMNIPOD® 5 AUTOMATED INSULIN DELIVERY (AID) SYSTEM IN PEOPLE WITH TYPE 2 DIABETES (T2D): SUB-ANALYSIS OF THE SECURE-T2D STUDY. Diabetes Technol Ther 2025; 27:e101-e102.
Document Type
Conference Proceeding
Publication Date
3-1-2025
Publication Title
Diabetes Technol Ther
Abstract
Background and Aims: Many people with T2D may not use carbohydrate counting for meal bolusing, so it is important to understand whether simplified meal bolus approaches can be used with AID. The Omnipod® 5 AID System demonstrated safety and efficacy in adults (≥18y) with T2D and was recently cleared by the US FDA for use in this population (also FDA cleared/CE marked for ages ≥2y with type 1 diabetes). This SECURE-T2D sub-analysis evaluated outcomes by bolus strategy with AID use. Methods: This multicenter single-arm trial enrolled insulintreated adults aged 18-75y with T2D with HbA1c <12.0%. After a 14-day period to capture baseline data, participants received carbohydrate counting training and were advised to carbohydrate count or use a simplified bolus strategy during the 13-week AID period. Glycemic outcomes according to bolus strategy used with AID were evaluated: carbohydrate counting, small/medium/large carbohydrate entry, or fixed carbohydrate entry. Results: A total of 305 participants (mean age 57-11y, 24% Black, 22% Hispanic/Latino, 21% using basal insulin without mealtime insulin, 55% using GLP1-RA) initiated AID. of the 289 who completed the study, 59% used carbohydrate counting, 35% used small/medium/large carbohydrate entry, 4% used fixed carbohydrate entry, and 2% used other or a combination strategy. Similar improvements in HbA1c, time in range, and time >250mg/dL (>13.9 mmol/L) were achieved across strategies, with time <70mg/dL (<3.9mmol/L) unchanged (Table). Participants delivered 3.2-1.7 (mean-SD) boluses/day. Conclusions: These results provide evidence that glycemic improvements among people with T2D using simplified bolus strategies are comparable to a carbohydrate counting based bolus strategy with the Omnipod 5 System.
Volume
27
First Page
e101
Last Page
e102
